Clincosm LogoSign in Get a demo

Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases

Sponsor
Heidelberg University (Other)
Overall Status
Unknown status
CT.gov ID
NCT00221832
Collaborator
(none)
300
Enrollment
1
Location
98
Duration (Months)
3.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of this study is the identification of familial congenital arrhythmogenic disorders and their clinical follow-up.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Molecular genetic screening in patients with:

    • supraventricular

    • ventricular arrhythmia

    • syncopes of unknown origin and/or suspicion of an arrhythmogenic origin

    • family members of patients with sudden cardiac death and aborted sudden cardiac death

    Examination of patients includes routine testing like electrocardiogram (ECG), sequential ECGs, exercise testing, invasive electrophysiological stimulation, cardiac magnetic resonance imaging, intravenous drug challenge for identification/exclusion of eg Brugada syndrome. Examples are patients with Long QT Syndrome, Short QT Syndrome, Brugada Syndrome, familial atrial fibrillation, WPW-syndrome, arrhythmias due to familial hypertrophic cardiomyopathy or arrhythmogenic right ventricular dysplasia. Blood samples are taken for further molecular genetic screening.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    300 participants
    Observational Model:
    Family-Based
    Time Perspective:
    Prospective
    Official Title:
    Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
    Study Start Date :
    Oct 1, 2003
    Anticipated Study Completion Date :
    Dec 1, 2011

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      N/A and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:

      • Patients with a history of syncope, abnormal ECG and suspicion of an arrhythmogenic disease

      • Patients with long QT syndrome

      • Patients with short QT syndrome, shortened QT intervals, borderline shortened QT intervals

      • Patients with Brugada syndrome

      • Patients with hypertrophic cardiomyopathy

      • Patients with arrhythmogenic right ventricular dysplasia

      Exclusion Criteria:
      • Inability to understand study protocol

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 University Hospital Mannheim, I. Department of Medicine Mannheim Germany 68167

      Sponsors and Collaborators

      • Heidelberg University

      Investigators

      • Study Director: Martin Borggrefe, Prof., MD, I. Department of Medicine-Cardiology

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00221832
      Other Study ID Numbers:
      • 0261.5
      First Posted:
      Sep 22, 2005
      Last Update Posted:
      Jan 13, 2010
      Last Verified:
      Oct 1, 2003
      Keywords provided by , ,
      Long QT Syndrome
      Hypertrophic cardiomyopathy
      arrhythmogenic right ventricular dysplasia
      Short QT Syndrome
      Brugada Syndrome
      Additional relevant MeSH terms:
      Cardiomyopathies
      Cardiomyopathy, Hypertrophic
      Long QT Syndrome
      Arrhythmogenic Right Ventricular Dysplasia
      Syndrome
      Hypertrophy

      Study Results

      No Results Posted as of Jan 13, 2010